Isosorbide Mononitrate Activase Pharmaceuticals (Isosorbide Mononitrate)

The drug is converted in the body to nitric oxide, which activates guanylate cyclase in vascular smooth muscle. This raises cyclic GMP levels, causing relaxation of both veins and arteries, lowering preload and afterload, and improving the balance between myocardial oxygen supply and demand.

Dosing is individualized based on the patient’s clinical condition, response, and tolerance. The prescribing healthcare professional determines the appropriate strength, frequency, and duration, and adjustments are made as needed during therapy.

Safety data in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with short‑acting nitrates such as nitroglycerin, isosorbide mononitrate offers a longer duration of action and once‑daily dosing, providing more stable symptom control. Unlike beta‑blockers, it does not affect heart rate, making it suitable for patients who cannot tolerate beta‑blockade.

Store the medication at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally, usually with a glass of water. Tablets should be swallowed whole and not crushed or chewed, unless the prescribing information specifies otherwise. Doses are typically spaced evenly throughout the day as directed by the prescriber.

The most serious adverse events include severe hypotension, syncope, myocardial infarction triggered by abrupt nitrate withdrawal, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, chest pain, or signs of an allergic response.

Individuals with known hypersensitivity to isosorbide mononitrate or any other organic nitrates should avoid the drug. It is also contraindicated in patients with severe hypotension, concurrent use of other nitrate preparations, or those taking phosphodiesterase‑5 inhibitors without medical supervision.